Annual CFF
$7.61 M
+$3.33 M+77.84%
December 1, 2023
Summary
- As of February 8, 2025, DRMA annual cash flow from financing activities is $7.61 million, with the most recent change of +$3.33 million (+77.84%) on December 1, 2023.
- During the last 3 years, DRMA annual CFF has risen by +$5.04 million (+196.28%).
- DRMA annual CFF is now -52.35% below its all-time high of $15.96 million, reached on December 31, 2021.
Performance
DRMA Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$4.62 M
+$2.28 M+97.30%
September 1, 2024
Summary
- As of February 8, 2025, DRMA quarterly cash flow from financing activities is $4.62 million, with the most recent change of +$2.28 million (+97.30%) on September 1, 2024.
- Over the past year, DRMA quarterly CFF has increased by +$2.66 million (+136.21%).
- DRMA quarterly CFF is now -67.92% below its all-time high of $14.39 million, reached on September 30, 2021.
Performance
DRMA Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$8.91 M
+$4.65 M+109.23%
September 1, 2024
Summary
- As of February 8, 2025, DRMA TTM cash flow from financing activities is $8.91 million, with the most recent change of +$4.65 million (+109.23%) on September 1, 2024.
- Over the past year, DRMA TTM CFF has increased by +$1.30 million (+17.13%).
- DRMA TTM CFF is now -52.26% below its all-time high of $18.66 million, reached on June 30, 2022.
Performance
DRMA TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
DRMA Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +77.8% | +136.2% | +17.1% |
| 3 y3 years | +196.3% | +205.2% | +56.6% |
| 5 y5 years | +60.6% | +205.2% | +56.6% |
DRMA Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -52.4% | +77.8% | at high | >+9999.0% | -52.3% | +159.7% |
| 5 y | 5-year | -52.4% | +196.3% | -67.9% | >+9999.0% | -52.3% | -100.0% |
| alltime | all time | -52.4% | +196.3% | -67.9% | >+9999.0% | -52.3% | -100.0% |
Dermata Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $4.62 M(+97.3%) | $8.91 M(+109.2%) |
| Jun 2024 | - | $2.34 M(>+9900.0%) | $4.26 M(+24.1%) |
| Mar 2024 | - | $0.00(-100.0%) | $3.43 M(-54.9%) |
| Dec 2023 | $7.61 M(+77.8%) | $1.95 M(-5619.8%) | $7.61 M(+34.6%) |
| Sep 2023 | - | -$35.40 K(-102.3%) | $5.65 M(-0.6%) |
| Jun 2023 | - | $1.51 M(-63.8%) | $5.69 M(-32.7%) |
| Mar 2023 | - | $4.18 M(>+9900.0%) | $8.45 M(+97.6%) |
| Dec 2022 | $4.28 M | $0.00(-100.0%) | $4.28 M(+0.0%) |
| Sep 2022 | - | $200.00(-100.0%) | $4.28 M(-77.1%) |
| Jun 2022 | - | $4.28 M(>+9900.0%) | $18.66 M(+29.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | $0.00(-100.0%) | $14.39 M(-9.9%) |
| Dec 2021 | $15.96 M(+521.8%) | -$600.00(-100.0%) | $15.96 M(-1.9%) |
| Sep 2021 | - | $14.39 M(>+9900.0%) | $16.28 M(+396.9%) |
| Jun 2021 | - | $0.00(-100.0%) | $3.28 M(-20.9%) |
| Mar 2021 | - | $1.58 M(+403.1%) | $4.14 M(+61.4%) |
| Dec 2020 | $2.57 M(-45.8%) | $313.30 K(-77.4%) | $2.57 M(+13.9%) |
| Sep 2020 | - | $1.39 M(+59.7%) | $2.25 M(+159.7%) |
| Jun 2020 | - | $867.90 K(>+9900.0%) | $867.90 K(>+9900.0%) |
| Mar 2020 | - | $0.00 | $0.00 |
| Dec 2019 | $4.73 M | - | - |
FAQ
- What is Dermata Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Dermata Therapeutics?
- What is Dermata Therapeutics annual CFF year-on-year change?
- What is Dermata Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Dermata Therapeutics?
- What is Dermata Therapeutics quarterly CFF year-on-year change?
- What is Dermata Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Dermata Therapeutics?
- What is Dermata Therapeutics TTM CFF year-on-year change?
What is Dermata Therapeutics annual cash flow from financing activities?
The current annual CFF of DRMA is $7.61 M
What is the all time high annual CFF for Dermata Therapeutics?
Dermata Therapeutics all-time high annual cash flow from financing activities is $15.96 M
What is Dermata Therapeutics annual CFF year-on-year change?
Over the past year, DRMA annual cash flow from financing activities has changed by +$3.33 M (+77.84%)
What is Dermata Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of DRMA is $4.62 M
What is the all time high quarterly CFF for Dermata Therapeutics?
Dermata Therapeutics all-time high quarterly cash flow from financing activities is $14.39 M
What is Dermata Therapeutics quarterly CFF year-on-year change?
Over the past year, DRMA quarterly cash flow from financing activities has changed by +$2.66 M (+136.21%)
What is Dermata Therapeutics TTM cash flow from financing activities?
The current TTM CFF of DRMA is $8.91 M
What is the all time high TTM CFF for Dermata Therapeutics?
Dermata Therapeutics all-time high TTM cash flow from financing activities is $18.66 M
What is Dermata Therapeutics TTM CFF year-on-year change?
Over the past year, DRMA TTM cash flow from financing activities has changed by +$1.30 M (+17.13%)